CISD1 and cancer: Similarly, progression-free survival analysis indicated that patients with elevated CISD1 expression faced a heightened risk of death across multiple cancers: ACC (HR = 1.67, p = 5.1e-3), LIHC (HR = 1.35, p = 0.01), BLCA (HR = 1.28, p = 0.01), LUAD (HR = 1.33, p = 0.02), and SKCM (HR = 1.18, p = 0.05) (Fig. S2C), suggesting that the progression of the disease cannot be effectively controlled by the treatment of these cancers.